Ex-corporate now wants to find a cure for dementia

LONDON: A high flying ex-corporate has now set his mind to finding a cure for dementia.

Gavin Patterson, the former boss of BT and senior executive at Salesforce, has been appointed as the chair of Alzheimer’s Research UK, becoming the latest senior business figure to help find a cure for Britain’s biggest killer.

In an exclusive interview, Patterson, 57, says he has committed to the role for the long term. “Over my lifetime, I’m hoping that we make a real breakthrough,” he adds.

The voluntary position forms part of Patterson’s growing portfolio of non-executive roles, which includes directorships at the online supermarket Ocado, Kraken, the technology platform, and Kahoot, the educational company, since he left the United States two years ago. In the corporate world, he was, until 2023, chief strategy officer at Salesforce, the $329 billion software giant.

Speaking at The Park, a restaurant near Hyde Park in London, he explains that the “mission is critical” for Britain’s health system and economy and, unlike his predecessors, fortunately he has not experienced first-hand the devastating disease.

“I’m unusual on the board because I don’t know somebody directly in my family who’s suffering from dementia … if nothing changes, one in two of us will be directly affected by dementia — either by caring for someone with the condition, developing it ourselves or both,” he says.

Kate Swann, 60, the former chief executive of WH Smith and SSP Group, who was chair briefly from 2022, witnessed the “truly heartbreaking” impact dementia had on her mother, who she described as “a force of nature; the matriarch of our family”.

Despite the threat of the disease in the UK, where almost one million people are living with dementia, there are no treatments available on the NHS to slow, stop or prevent it. It is estimated to cost £42 billion a year and families foot almost two thirds of the expense, according to Alzheimer’s Research UK.

Since the charity was founded in 1992, it has invested more than £237 million in dementia research, helping to fund drug discovery research, diagnostics and scientific understanding of the genetics of the condition. Last year, it invested about £27 million.

Income has grown to £57 million, and the board wants to double it. The appointment of Patterson, who will formally succeed Mike Cooper on February 12, came about after contact from David Mayhew, the vice-chairman of JPMorgan’s global investment bank. Mayhew, 84, was chairman for more than a decade before becoming vice-president in 2023. The two know each from Patterson’s time running BT.

After a 34-year corporate career, which included marketing roles at Procter & Gamble, the consumer goods corporation, and Telewest, a broadband firm, Patterson will aim to tap into his network on both sides of the Atlantic to help raise funding and awareness, including of lifestyle choices and among employers.

“I mean, it’s not as though dementia only affects people who are retired,” he says. “It can affect people earlier. And in many cases the carers are family members who have to take time off work to look after the person, so it is an issue that employers need to take seriously.”

The charity is based at Granta Park, a technology and scientific campus in Cambridge, and the research it has helped fund is “beginning to have an impact”, he says.

“But when you see the scale of the problem and you look at the treatments that are available, the understanding of what causes the condition … you realise that there is a long way to go.”

In October, the drug donanemab, made by Eli Lilly, the world’s biggest pharma company, which has been shown to slow the progress of Alzheimer’s disease by several months, was rejected for use on the NHS.

Nice, the health watchdog, said it “does not currently demonstrate value for the NHS” and its cost-effectiveness estimate was five to six times above what the regulator normally considers an acceptable use of NHS resources.

The drug has been deemed safe and effective by the Medicines and Healthcare Products Regulatory Agency (MHRA) for patients in the early stages of Alzheimer’s and is available in Britain for those who can pay for it, although charities said it would be “unaffordable for the vast majority of people”.

Similarly, two months earlier, the drug lecanemab was rejected for NHS use despite also being approved by the MHRA.

Both drugs are designed to help clear amyloid, a protein that builds up in the brains of people with Alzheimer’s, and to slow memory and thinking problems.

Patterson is concerned about the lack of funding and investment for serious health conditions compared with oncology, where Big Pharma, including AstraZeneca, Britain’s biggest public company, has made important breakthroughs and treatments have become more effective, safer and cheaper.

“Where there are treatments available, or your speed of getting access to them is being curtailed because of budgets, essentially, and affordability, then that’s deeply frustrating for people,” he says.

The potential of artificial intelligence presents a “once in a lifetime” opportunity to accelerate drug development, including by mining NHS health records, and moving to a model where there is a “mixture of paid and free at the point of use” are, he believes, the solutions.

“I think relying on everything to be free is something that has to change. Easy to say but difficult to change. And I think we need to take a longer term view,” he adds.

Patterson, who has four adult children with his American wife, did that personally when he decided to end his career in executive leadership.

“I finished at Salesforce in January 2023 and at that point I knew I was done,” he says. “CEO jobs … they’re a lot harder than they’re portrayed for the glamour and the profile and obviously the money. There’s a lot of trade-offs and a lot of sacrifices. They do affect your health and your relationships.”

When Mayhew came calling, the board was “looking for somebody who had not just the personal time to put into it, but the years ahead of them”, Patterson says, adding: “Hopefully.”